Baxfendy Hypertension Treatment: FDA Approves First-in-Class Aldosterone Synthase Inhibitor

Baxfendy hypertension treatment received US Food and Drug Administration approval as the first aldosterone synthase inhibitor for adults with hypertension not adequately controlled on other antihypertensive medications. AstraZeneca’s Baxfendy (baxdrostat) demonstrated statistically significant and clinically meaningful seated systolic blood pressure reductions in the BaxHTN Phase III trial at both the 2 mg and 1 mg doses when added to standard of care.

Pioneering Option for Resistant Hypertension

These results position Baxfendy hypertension treatment as a novel therapeutic option targeting aldosterone production directly in patients with uncontrolled or resistant hypertension. In the BaxHTN trial, the 2 mg dose produced an absolute reduction in mean seated systolic blood pressure of 15.7 mmHg from baseline at week 12, corresponding to a placebo-adjusted reduction of 9.8 mmHg.

Trial Data Reveal Clear Systolic Gains

The 1 mg dose yielded an absolute reduction of 14.5 mmHg and a placebo-adjusted reduction of 8.7 mmHg, with consistent effects observed across both uncontrolled and treatment-resistant subgroups. These findings are reinforced by supporting statements from trial investigators noting that a 10 mmHg systolic reduction is associated with approximately a 20 percent lower risk of major cardiovascular events.

How BaxHTN Tested Aldosterone Inhibition

The BaxHTN Phase III study enrolled 796 patients randomized in a 1:1:1 ratio to receive baxdrostat 2 mg, 1 mg, or placebo once daily on top of background antihypertensive therapy, with the primary endpoint defined as the change from baseline in seated systolic blood pressure at week 12. Baxdrostat development details describe Baxfendy as a highly selective oral small molecule that inhibits aldosterone synthase, the enzyme encoded by CYP11B2, thereby lowering aldosterone levels without affecting cortisol.

Shifting Cardiovascular Outcomes and Access

The approval introduces a first-in-class mechanism that may alter treatment pathways for the substantial population of patients whose hypertension remains uncontrolled despite multiple medications, potentially influencing Health Economics and Outcomes Research evaluations of cardiovascular event prevention and resource utilization. By targeting aldosterone production at its source, Baxfendy could support more favorable assessments of long-term outcomes such as reduced incidence of heart failure, kidney disease progression, and stroke.